The importance of apoptotic activity and plasma NT-proBNP levels in patients with acute exacerbation of decompensated heart failure and their relation to different drugs and comorbidities

Journal of the Pakistan Medical Association

Volumn 64, Issue 8, 2014, Pages 884-891

  Gultekin, Nazmi ^a   Kucukates, Emine ^a   Yildiz, Ahmet ^a   Kocas, Cuneyt ^a   Ersanli, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apoptotic activity; Comorbidity; Decompensated heart; NT proBNP levels

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ACUTE HEART FAILURE; ADULT; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CHEMILUMINESCENCE IMMUNOASSAY; COMORBIDITY; DEATH; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFECT; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC CARDIOMYOPATHY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION;

AGED; APOPTOSIS; BIOLOGICAL MARKERS; COMORBIDITY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TURKEY;

EID: 84904737902     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U. S. 1979-2004. J Am Coll Cardiol 2008; 52: 428-34
2. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. ADHERE Scientific Advisory Commitee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompansated heart failure: classification and regression tree analysis. JAMA2005; 293: 572-80
3. Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011; 58: 1881-9
4. Biolo A, Fisch M, Balog J, Chao T, Schulze PC, Ooi H, et al. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010; 3: 44-50
5. Maisel A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol 2011; 58: 1890-2
6. O'Connor CM, Fiuzat M, Lombardi C, Fujita K, Jia G, Davison BA, et al. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. Circ Heart Fail 2011; 4: 724-32
7. Clerio A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50
8. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N- terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-74
9. Ancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, et al. FUSION II Investigators. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the second follow-up serial infusions of nesiritide (Fusion II) trial. Circ Heart Fail 2008;1: 9-16
10. Kang PM, Izumo S. Apoptosis and heart failure: A critical review of the literature. Circ Res 2000; 86: 1107-13
11. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, et al. Apoptosis is myocytes in the end - stage heart failure. N Eng J Med 1996; 335: 1182-9
12. Anversa P, Kajstura J, Olivetti G. Myocyte death in heart failure. Curr Opin Cardiol 1996; 11: 245-51
13. Sohn HJ, Yoo KH, Jang GY, Lee JH, Choi BM, Lee JH, et al. Aldosterone modulates cell proliferation and apoptosis in the neonatal rat heart. J Korean Med Sci 2010; 25: 1296-304
14. Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009; 30: 789-96
15. Di Somma S, Magrini L, Tabacco F, Marino R, Talucci V, Marrocco F, et al. Brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide show a different profile in response to acute decompensated heart failure treatment. Congest Heart Fail 2008; 14: 245-50
16. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-504
17. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, et al. Management of chronic heart failure guided by individual N-Terminal Pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure improve heart failure improve heart failure morbidity and mortality?) study. J Am Coll Cardiol 2010; 56: 2090-100
18. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93: 1309-12
19. Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kytö V, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol2007; 150: 851-61
20. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002; 45: 73-85
21. Palfi A, Toth A, Hanto K, Deres P, Szabados E, Szereday Z, et al. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3? pathway. J Mol Cell Cardiol 2006; 41: 149-59
22. Chan NY, Seyedi N, Takona K, Levi R. An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation 2012; 125: 298-307
23. Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, et al. Possible involment of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998; 82: 166-74
24. Kramer JH, Weglicki B. A hydroxylatedanalog of the betaadrenoceptor blocker antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radic Biol Med 1996; 21: 813-25
25. Communal C, Singh K, Pimentel DR, Colussi WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta adrenergic pathway. Circulation 1998; 98: 1329-34.